- Raphaël joined Andera Partners in 2001.
- Since joining Andera he has worked on numerous investments, M&As and IPOs. Raphaël has in depth experience in all types of transactions gained both in banking and in Venture Capital.
- He sits on the boards of Dualyx, BioVentrix, ImCheck, Amolyt Pharma, Poxel, Grey Wolf Therapeutics, Enyo Pharma, Dynacure, Artios, AM Pharma and Exciva. He was also a board member of Reviral, Axonics Modulation Technologies, Novagali Pharma, Pangenetics, Chase Pharmaceuticals, Oncoethix and Vessix Vascular until their acquisition by large pharmaceutical or medical device companies.
- Raphaël began his career in London, where he spent seven years in the healthcare and investment banking industries. He was first part of the finance department of Générale de Santé International in London, the largest private hospitals group in the UK, where he held treasury and investment analysis functions.
- He subsequently worked in the healthcare groups of the Investment Banking divisions of Salomon Smith Barney (1996-1999) and Goldman Sachs (1999-2001). During his years in investment banking, Raphaël participated in many M&A and capital raising deals within pharmaceuticals, medical devices, biotechnology and services companies.
- Raphaël graduated from the French business school HEC in 1993 and received a Master’s in Applied Economics from Institut d’Etudes Politiques in 1994.
20 years to sow
Investments of Raphaël
Dualyx
Biotech developing novel Treg therapies for autoimmune diseases
BioVentrix
Development of clinical solutions for the treatment of patients suffering from heart failure
Imcheck
New generation of antibody-based immunotherapy for the treatment of cancer and autoimmune diseases
Amolyt Pharma
Developing therapeutic peptides for rare endocrine and related diseases
AM Pharma
Protéine recombinante pour le traitement de l'insuffisance rénale aiguë causée par le sepsis
Atlantic Therapeutics
Dispositif d'électrostimulation pour l’incontinence urinaire d’effort
Enyo Pharma
Petites molécules pour le traitement de l’hépatite B chronique et de la NASH
GreyWolf Therapeutics
Petites molécules pour rendre les tumeurs détectables par le système immunitaire
Erytech
Nouvelle thérapie enzymatique pour le traitement de tumeurs solides et liquides
MedDay Pharmaceuticals
Petite molécule pour le traitement de la sclérose en plaques progressive
ReViral
Petites molécules pour le traitement des infections par le Virus Respiratoire Syncytial
Axonics
Neurostimulateur implantable pour le traitement de l'incontinence urinaire
Poxel
Développement de médicaments pour le traitemennt du Diabète de type II
AM Pharma
Recombinant protein for the treatment of Sepsis-Associated Acute Kidney Injury
Flamingo Therapeutics
Antisense oligonucleotides for the treatment of cancers
Artios Pharma
Small molecules for the treatment of cancer
Exciva
Small molecule for the treatment of behavioral and psychological symptoms of dementia in AD
MedDay Pharmaceuticals
Small molecule for the treatment of progressive multiple sclerosis
ReViral
Small molecules as a therapeutic treatment for RSV infection
Axonics
Neuromodulation technology for the treatment of incontinence
Poxel
Development of small molecules for the treatment of Type 2 diabetes
CHASE Pharmaceuticals
Novel approach to increase efficacy and safety of marketed Alzheimer's drugs
Oncoethix
Small molecules for haematological cancer treatment
The team andera Life Sciences
Thierry Hercend
Venture Partner
Gilles Nobécourt
Partner
Aneta Sottil
Director
Mathieu Piéronne
Investment Director
Jan Van den Bossche
Partner
Sofia Ioannidou
Partner
Raphaël Wisniewski
Partner
Olivier Litzka
Partner
Elyes Chouaieb
Investment Manager
Loan Hoang-Sayag
Venture Partner
Florian Gerard-Mercier
Investment Manager
Yuexin Yu
Investment Director
Emmanuelle Payet
Middle Office
Raymond W. Cohen
Venture Advisor
Natali Romero Barrios
Investment Manager
Yanis Feraoun
Analyst
Vanessa Bonvalot
Executive Assistant
